Compare BioNano Genomics Inc (BNGO) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Msci Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Msci Inc trades at $629.85 (market cap $44.51B). The key difference: Msci Inc is far larger — about 3372× BioNano Genomics Inc's market cap, and Msci Inc pays a 1.34% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MSCI | |
|---|---|---|
Market Cap | $13.20M | $44.51B |
Sector | Health | Financials |
52-Week High | $4.92 | $643.83 |
52-Week Low | $1.09 | $511.84 |
Enterprise Value | $15.81M | $50.68B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
MSCI trades at $620.23, up 2.57% with bullish technical signals and strong earnings beats. The company shows robust fundamentals with 2025 revenue of $3.13B and net income of $1.20B, supported by high margins. Recent news highlights strategic partnerships with UBS and acquisitions to enhance private markets and climate risk capabilities, reinforcing growth prospects amid positive analyst sentiment.
Outlook remains positive with a consensus price target of $718.14, though elevated P/E of 35.42 and high debt levels pose valuation and financial risks. Earnings growth and strategic expansions are key catalysts, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
